A method is provided for treating pathogens with a lipid-based carrier and organic acids. More specifically the lipid carrier may have a pKa of 2.5-4.0 and/or may be acid oil, such as Acidulated Vegetable Oil. Furthermore, compositions consistent with the method are provided wherein the lipid-based carrier increases antipathogenic action of the organic acid. For example, the carrier may have a pKa that increases the antimicrobial action of the organic acid and/or an additional essential oil. The carrier may be acid oil, such as Acidulated Vegetable Oil derived from soapstocks and/or gums, but is not limited to same. The organic acid may include, but is not limited to, formic acid, acetic acid, propionic acid, butyric acid, and combinations thereof.

A nutraceutical dietary supplement formulation for the treatment of joint pain and discomfort may include astaxanthin powder; boswellia serrate gum resin extract; hyaluronic acid; undenatured type II (UC-II) collagen; eggshell membrane collagen powder; turmeric root extract; white willow bark extract; cayenne pepper extract; and Cat's Claw bark powder. The formulation may be formed into capsules for delivery to a user, wherein a therapeutically effective dosage of the formulation may be included in each capsule.

A nutraceutical dietary supplement formulation for the treatment of joint pain and discomfort may include astaxanthin powder; boswellia serrate gum resin extract; hyaluronic acid; undenatured type II (UC-II) collagen; eggshell membrane collagen powder; turmeric root extract; white willow bark extract; cayenne pepper extract; and Cat's Claw bark powder. The formulation may be formed into capsules for delivery to a user, wherein a therapeutically effective dosage of the formulation may be included in each capsule.

The present invention relates to a composition for preventing, treating, or alleviating ischemia-reperfusion injury, containing bile acid. According to the present invention, bile acid increases intranuclear beta-catenin levels, interferes with the opening of a mitochondria permeable transition pore (mPTP), and has excellent effects, in ischemia-reperfusion injury animal models, of alleviating tissue injury and reducing the size of infarcts, thereby being usable in the prevention, treatment, or alleviation of ischemia-reperfusion injury.

The present invention relates to a composition for preventing, treating, or alleviating ischemia-reperfusion injury, containing bile acid. According to the present invention, bile acid increases intranuclear beta-catenin levels, interferes with the opening of a mitochondria permeable transition pore (mPTP), and has excellent effects, in ischemia-reperfusion injury animal models, of alleviating tissue injury and reducing the size of infarcts, thereby being usable in the prevention, treatment, or alleviation of ischemia-reperfusion injury.

Producing sauce (e.g., mayonnaise) using animal fat on a commercial scale to obtain the quantity, quality, and life of traditional commercial-grade sauce made with common fruit, nut, seed, flower, and vegetable oils. An industrial-grade emulsifying machine such as a high-shear mixer is utilized to ensure that the animal fat particles are made sufficiently small to produce a good emulsion. An anti-rancidity or antioxidant (e.g., vitamin E, rosemary oil extract (ROE), bovine casein hydrolysate (BCH)) is utilized to prevent the animal fat from becoming rancid and enabling longer shelf life. The animal fat offers many benefits over traditional fruit, flower, nut, vegetable, and seed oils including being cheaper and more plentiful commercially, better-tasting and health benefits, including anti-carcinogenic properties.

A method is provided for treating pathogens with a lipid-based carrier and organic acids. More specifically the lipid carrier may have a pKa of 2.5-4.0 and/or may be acid oil, such as Acidulated Vegetable Oil. Furthermore, compositions consistent with the method are provided wherein the lipid-based carrier increases antipathogenic action of the organic acid. For example, the carrier may have a pKa that increases the antimicrobial action of the organic acid and/or an additional essential oil. The carrier may be acid oil, such as Acidulated Vegetable Oil derived from soapstocks and/or gums, but is not limited to same. The organic acid may include, but is not limited to, formic acid, acetic acid, propionic acid, butyric acid, and combinations thereof.

A method is provided for treating pathogens with a lipid-based carrier and organic acids. More specifically the lipid carrier may have a pKa of 2.5-4.0 and/or may be acid oil, such as Acidulated Vegetable Oil. Furthermore, compositions consistent with the method are provided wherein the lipid-based carrier increases antipathogenic action of the organic acid. For example, the carrier may have a pKa that increases the antimicrobial action of the organic acid and/or an additional essential oil. The carrier may be acid oil, such as Acidulated Vegetable Oil derived from soapstocks and/or gums, but is not limited to same. The organic acid may include, but is not limited to, formic acid, acetic acid, propionic acid, butyric acid, and combinations thereof.

A method of improving mouthfeel and masking perceived astringency and undesired off-notes imparted by a consumable composition or additive, including the step of adding to the consumable or additive an astringency-masking amount of hyaluronic acid and/or salt thereof, wherein the hyaluronic acid and/or salt thereof has an average molecular weight of at least 500 kDa. Additionally disclosed is a food or beverage additive comprising at least one astringent component and an astringency-masking amount of hyaluronic acid and/or salt thereof. Further disclosed is a consumable composition comprising a consumable base, at least one astringent component and an astringency-masking amount of hyaluronic acid and/or salt thereof.

A method of improving mouthfeel and masking perceived astringency and undesired off-notes imparted by a consumable composition or additive, including the step of adding to the consumable or additive an astringency-masking amount of hyaluronic acid and/or salt thereof, wherein the hyaluronic acid and/or salt thereof has an average molecular weight of at least 500 kDa. Additionally disclosed is a food or beverage additive comprising at least one astringent component and an astringency-masking amount of hyaluronic acid and/or salt thereof. Further disclosed is a consumable composition comprising a consumable base, at least one astringent component and an astringency-masking amount of hyaluronic acid and/or salt thereof.